Tag:
Tuberculosis Vaccine
Latest Headlines
Latest Headlines
Serum targets Merck, Sanofi stronghold with TB vax deal
Serum Institute of India has a history of winning shares in established vaccine markets by undercutting the competition. And now it has bought the rights to a tuberculosis vaccine it believes can beat shots by Merck and Sanofi on effectiveness, as well as cost.
Despite setback, TB vaccine study is a step in the right direction
While a closely watched study of Gates-backed TB vaccine MVA85A failed to produce the desired results to guard against infection in infants, a dozen more vaccine candidates are being tested in humans. Regardless of results, the first efficacy trial of a new TB vaccine is a milestone.
Tuberculosis vaccine may reverse Type 1 diabetes
A 90-year-old tuberculosis vaccine may help reverse Type I diabetes, Harvard University researchers say.
Oral TB vax could cut treatment time
Phase II results of Immune Network's therapeutic tuberculosis vaccine were presented at the Drug Resistance and Persistence in Tuberculosis meeting in Uganda, part of the Keystone Symposia Global Health Series.
TB vaccine in South African trials; blueprint will drive development
A new TB vaccine is expected to complete the first advanced clinical trials in South Africa in 2013.
Aeras, CNBG team on TB vaccine deal
Non-profit developer Aeras is teaming up with the China National Biotec Group (CNBG) to jointly develop new tuberculosis vaccines. Financial details of the deal were not disclosed. CNBG and...
TapImmune, Aeras team on TB vaccine
TapImmune has signed a deal with non-profit development group Aeras for preclinical work on a tuberculous vaccine. TapImmune's technology is designed to make vaccines more effective by boosting
Related bacterium could create viable TB vax
The current tuberculosis vaccine--bacille Calmette-Guérin (BCG)--has produced varying efficacy rates worldwide, ranging from 0% to 80%. In a new study published in Nature Medicine, however,
Aeras kicks off TB trial in HIV patients
In an effort to combat tuberculosis, Aeras and the Oxford-Emergent Tuberculosis Consortium have announced the start of a Phase IIb trial of the MVA85A vaccine. The 1,400-person proof-of-concept study
Study: Timing of new TB vaccine matters
A experimental vaccine for tuberculosis, called MVA85A, is more effective when give alone than in combination with other childhood shots. The next-generation vaccine is being developed by Emergent
